Table 3.
Summary of previous studies investigating single nucleotide polymorphisms and haplotypes of allergy-associated genes.
| First Author (Year) | Journal | Country | No. Cases/Controls | SNPs assessed (gene) | Outcome | Gene | SNP | Allele Comparison | OR (95% CI)a |
|---|---|---|---|---|---|---|---|---|---|
| Schwartzbaum (2005) [13] | Cancer Res | Sweden | 111/422b | rs1805015, rs1801275 (IL4R); rs20541, rs1800925 (IL13); rs2280091 (ADAM33); -765GC (COX-2) | GBM | IL4R | rs1805015 | TC, CC vs. TT | 1.64; 1.05–2.55 |
| rs1801275 | AG/AA vs. GG | 1.61; 1.05–2.47 | |||||||
| IL-13 | rs1800925 | CC/TC vs. TT | 0.56; 0.33, 0.96 | ||||||
| Schwartzbaum (2007) [14] | Cancer Epi Biomarkers Prevention | Sweden, UK, Denmark, Finland | 327/1,607b | rs1805015, rs1801275 (IL4R); rs20541, rs1800925 (Il13); - 765GC (COX-2); IL4Ra and IL-13 haplotypes | GBM | IL4R | rs1805015, rs1801275 | T-G haplotype | 2.26; 1.13, 4.52 |
| Brenner (2007) [8] | Carcinogenesis | US | 798/1,175 | rs2243248, rs2243248, rs2070874 (IL4); rs1801275 (IL4R); rs2069812 (IL5); rs1800795 (IL6); rs1800871, rs1800872, rs1800896 (IL10); rs568408 (IL12A); rs20541 (IL13) | Glioma | IL4 | rs2243248 | GT vs. TT | 1.44; 1.05, 1.97 |
| GT/GG vs. TT | 1.49; 1.10–2.03 | ||||||||
| IL6 | rs1800795 | GG vs. TT | 0.70; 0.51, 0.95 | ||||||
| GBM | IL4 | rs2243248 | GT/GG vs. TT | 1.47; 1.00–2.17 | |||||
| Dobbins (2010) [9] | Int J Cancer | UK, US | 1,878/3,670 | rs7216389 (ORMDL3); rs1420101 (IL1RL1); rs1588265 (PDE4D); rs7130588 (C11orf30) | Glioma | ORMDL3 | rs7216389 | CT vs. CC | 1.16; 1.01–1.32 |
| TT vs. CC | 1.20; 1.02–1.41 | ||||||||
| Ruan (2011) [10] | Front Biosci (Elite ed) | China | 806/910 | rs20541 (IL13); rs1801275 (IL4Ra); rs1059513, rs324015 (STAT6) | Glioma (never- smokers) | STAT6 | rs1059513 | GG vs. AA | 1.691; 1.152–2.481 |
| rs1059513, rs324015 | A-G haplotype | 1.321; 1.081– 1.614 | |||||||
| GBM | rs1059513 | GG vs. AA | 1.856; 1.153– 2.987 | ||||||
| Amirian (2010) [7] | Neuro- Oncology | US | 373/365 | rs2243250, rs2070874 (IL4); rs1805011, rs1805012, rs1805015, rs1801275, rs1805016 (IL4R); rs1800896, rs1800871, rs1800872 (IL10); rs20541, rs1800925 (IL13); rs16944, rs1143627(IL1B); rs2069762 (IL2); rs1800795, rs1800796, rs1800797 (IL6); rs187238 (IL18); rs20417 (COX2/PTGS2); rs1020759 (NFKB1); rs569108 (MS4A2); haplotypes for IL1, IL4, IL4R, IL6, IL10 | Glioma | IL10 | rs1800896 | GG vs. AA/GA | 1.57; 1.11–2.23 |
| IL13 | rs20541 | TT vs. CC | 0.39; 0.17–0.94 | ||||||
| TT vs. CC/CT | 0.39; 0.16–0.93 | ||||||||
| Cox2 | rs20417 | CG vs. CC | 1.43; 1.02, 1.98 | ||||||
| CG/GG vs. CC | 1.41; 1.01–1.96 | ||||||||
| GBM | IL10 | rs1800896 | GG vs. A/GA | 1.61; 1.07–2.44 | |||||
| Scheuerer (2008) [11] | Clinical Cancer Res | US | 694 cases | rs243250 (IL4); rs1800925 (IL13); rs1805011, rs1805012, rs1805015, rs1801275, rs1805016 (IL4R); IL4R haplotype | High- grade overall glioma survival Post 1- year high-grade glioma survival | IL4R | rs1805016 | TT vs. GT/GG | 0.59; 0.40–0.87 |
| rs1805015 | TT vs. CT/CC | 0.63; 0.44–0.91 | |||||||
| rs1805016 | TT vs. GT/GG | 0.44; 0.27–0.73 | |||||||
| rs1805011, rs1805012, rs1805015, rs1801275, rs1805016 | ATTAT haplotype | 0.68; 0.48–0.96 | |||||||
| Wiemels (2007) [15] | Cancer Epi Biomarkers Prevention | US | 456/541 | rs1805010, rs1805011, rs1805012, rs1805015, rs1801275, rs1805016 (IL4R); rs2243250, rs2070874 (IL4); rs1800925, rs20541 (IL13); IL4, IL4R, IL13 haplotypes | Glioma | IL4 | rs2243250 | TC vs. CC | 0.74; 0.55–1.0 |
| IL13 | rs1800925 | TC/TT vs. CC | 0.77; 0.57–1.0 | ||||||
| IL4 | rs2243250, rs2070874 | C-T haplotype | 0.22; 0.06–0.78 |
a
Only significant ORs are reported in this table.
b
Cases and controls from Schwartzbaum et al. 2005 are included in Schwartzbaum et al. 2007
Note: SNP: single nucleotide polymorphism; OR: odds ratio; CI: confidence interval; GBM: glioblastoma multiforme; UK: United Kingdom; US: United States